Johnson & Johnson reported robust financial results for the second quarter of 2025, exceeding Wall Street expectations. The company posted adjusted earnings of $2.77 per share against an analyst consensus of $2.68 per share. Quarterly sales reached $23.74 billion, surpassing analyst expectations of $22.84 billion. This performance was primarily fueled by strong sales in its Innovative Medicine segment, including drugs like Darzalex, Tremfya, Carvykti, Erleada, and Rybrevant/Lazcluze, as well as growth in its MedTech unit, particularly in electrophysiology products and surgical tools. Although sales of Stelara saw a decline, the overall strength of other products helped offset this impact.
Following these strong results, J&J has increased its financial guidance for 2025. The company now expects adjusted earnings per share between $10.80 and $10.90, up from its previous forecast of $10.50 to $10.70. This updated guidance for 2025 represents an increase of about $0.25 at the midpoint. J&J also raised its 2024 sales forecast by approximately $2 billion, setting a new range of $93.2 billion to $93.6 billion.
For 2026, J&J projects operational sales to be between $99.5 billion and $100.5 billion, exceeding analyst estimates of $98.9 billion. The company anticipates full-year 2026 profit to be in the range of $11.43 to $11.63 per share, aligning with analyst expectations around $11.45 per share. J.P. Morgan analyst Chris Schott noted that while a weaker dollar contributed about $0.17 to the $0.25 profit guidance boost, J&J's core business remains strong and is on track for consistent sales growth of 5% or more.
CEO Joaquin Duato highlighted that the company's diversified business across MedTech and Innovative Medicine, along with a strong pipeline, positions it for elevated growth in the second half of the year. Significant progress in new product development, including the approval of IMAAVY, priority review for TAR-200, and positive data for CARVYKTI, further supports this optimistic outlook. The company also factored in a "hundreds of millions of dollars" impact from a U.S. drug pricing agreement related to Trump-era tariffs when formulating its outlook.
